Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 6/20 | 0.54 |
| ▸ | ESR1 | P03372 | 5/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 7/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 5/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3750368 | 0.82 | ALDH1A1 (0.53) | SLC6A4ESR1SLC6A2CHRM2CYP2C19 | |
| SCHEMBL11493890 | 0.82 | ESR1 (0.57) | SLC6A4ESR1SLC6A2CHRM2CYP2C19 | |
| SCHEMBL27804186 | 0.82 | ALDH1A1 (0.53) | SLC6A4ESR1SLC6A2CHRM2CYP2C19 | |
| SCHEMBL9197781 | 0.82 | ESR1 (0.60) | SLC6A4ESR1SLC6A2CHRM2CYP2C19 | |
| SCHEMBL4108527 | 0.81 | PGR (0.53) | SLC6A4ESR1CYP2C19PGRLMNA | |
| SCHEMBL11494073 | 0.79 | ESR1 (0.55) | SLC6A4ESR1SLC6A2CHRM2CYP2C19 | |
| SCHEMBL11277156 | 0.79 | ESR1 (0.55) | SLC6A4ESR1SLC6A2CHRM2CYP2C19 | |
| SCHEMBL11855239 | 0.76 | ESR1 (0.55) | SLC6A4ESR1SLC6A2CHRM2CYP2C19 | |
| SCHEMBL11866439 | 0.74 | SLC6A4 (0.61) | SLC6A4ESR1SLC6A2CHRM2CYP2C19 | |
| SCHEMBL3739481 | 0.73 | ALDH1A1 (0.58) | SLC6A4ESR1SLC6A2CHRM2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2178899-B1 | 17BETA-CYANO-18A-HOMO-19-NOR-ANDROST-4-ENE DERIVATIVE, USE THEREOF AND MEDICAMENTS CONTAINING SAID DERIVATIVE | BAYER IP GMBH (DE) | 2012-10-24 | — | — | EP | claimed |
| US-20090048218-A1 | 17Beta-CYANO-18A-HOMO-19-NOR-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-02-19 | — | — | US | claimed |
| US-20090048218-A1 | 17Beta-CYANO-18A-HOMO-19-NOR-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-02-19 | — | — | US | disclosed |
| US-20090048218-A1 | 17Beta-CYANO-18A-HOMO-19-NOR-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048218-A1 | 17Beta-CYANO-18A-HOMO-19-NOR-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | HSD17B7, HSD17B11, CYP17A1 | SLC6A4 2758/4885ESR1 57/4885SLC6A2 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.